Maravai LifeSciences
MRVI
229 hedge funds and large institutions have $5.36B invested in Maravai LifeSciences in 2021 Q4 according to their latest regulatory filings, with 56 funds opening new positions, 89 increasing their positions, 60 reducing their positions, and 53 closing their positions.
151% more call options, than puts
Call options by funds: $11.4M | Put options by funds: $4.57M
48% more repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 60
6% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 53
0% more funds holding
Funds holding: 228 → 229 (+1)
14.26% less ownership
Funds ownership: 111.7% → 97.44% (-14%)
14% less capital invested
Capital invested by funds: $6.27B → $5.36B (-$907M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Select Equity Group
New York
|
+$341M |
| 2 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$99.6M |
| 3 |
BlackRock
New York
|
+$57.5M |
| 4 |
AAM
Ardevora Asset Management
London,
United Kingdom
|
+$57.2M |
| 5 |
AIM
Artemis Investment Management
Edinburgh,
United Kingdom
|
+$37.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$210M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$73M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$62.9M |
| 4 |
DCP
D1 Capital Partners
New York
|
-$49.1M |
| 5 |
GCM
Ghisallo Capital Management
Boston,
Massachusetts
|
-$46.6M |
MRVI Hedge Fund Activity: Q4 2021 in Review
229 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Maravai LifeSciences (MRVI) for Q4 2021, worth a combined $5.36B — down 14% from $6.27B a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new MRVI positions and 53 closed out — a net gain of 3 holders — while 89 added to existing stakes and 60 trimmed.
The largest buyer was Select Equity Group, adding an estimated $341M. The largest seller was Fidelity Investments, cutting an estimated $210M.
- 229 institutional investors held Maravai LifeSciences (MRVI) as of Q4 2021, up from 228 in Q3 2021.
- Funds reported $5.36B of Maravai LifeSciences stock for Q4 2021, down 14% quarter-over-quarter.
- 56 funds opened new Maravai LifeSciences positions in Q4 2021 and 53 closed out, a net change of +3 holders.
- The largest Maravai LifeSciences buyer in Q4 2021 was Select Equity Group, an estimated $341M added.
- The largest Maravai LifeSciences seller in Q4 2021 was Fidelity Investments, an estimated $210M sold.
Based on aggregated 13F filings for Q4 2021.